| Literature DB >> 23527249 |
Juan M Murias1, Adwitia Dey, Oscar A Campos, Mehrbod Estaki, Katharine E Hall, Christopher W J Melling, Earl G Noble.
Abstract
This study examined the effects of 6 weeks of moderate- (MD) and high-intensity endurance training (HD) and resistance training (RD) on the vasorelaxation responsiveness of the aorta, iliac, and femoral vessels in type 1 diabetic (D) rats. Vasorelaxation to acetylcholine was modeled as a mono-exponential function. A potential mediator of vasorelaxation, endothelial nitric oxide synthase (e-NOS) was determined by Western blots. Vessel lumen-to-wall ratios were calculated from H&E stains. The vasorelaxation time-constant (τ) (s) was smaller in control (C) (7.2 ± 3.7) compared to D (9.1 ± 4.4) and it was smaller in HD (5.4 ± 1.5) compared to C, D, RD (8.3 ± 3.7) and MD (8.7 ± 3.8) (p<0.05). The rate of vasorelaxation (% · s(-1)) was larger in HD (2.7 ± 1.2) compared to C (2.0 ± 1.2), D (2.0 ± 1.5), RD (2.0 ± 1.0), and MD (2.0 ± 1.2) (p<0.05). τ vasorelaxation was smaller in the femoral (6.9 ± 3.7) and iliac (6.9 ± 4.7) than the aorta (9.0 ± 5.0) (p<0.05). The rate of vasorelaxation was progressively larger from the femoral (3.1 ± 1.4) to the iliac (2.0 ± 0.9) and to the aorta (1.3 ± 0.5) (p<0.05). e-NOS content (% of positive control) was greater in HD (104 ± 90) compared to C (71 ± 64), D (85 ± 65), RD (69 ± 43), and MD (76 ± 44) (p<0.05). e-NOS normalized to lumen-to-wall ratio (% · mm(-1)) was larger in the femoral (11.7 ± 11.1) compared to the aorta (3.2 ± 1.9) (p<0.05). Although vasorelaxation responses were vessel-specific, high-intensity endurance training was the most effective exercise modality in restoring the diabetes-related loss of vascular responsiveness. Changes in the vasoresponsiveness seem to be endothelium-dependent as evidenced by the greater e-NOS content in HD and the greater normalized e-NOS content in the smaller vessels.Entities:
Mesh:
Year: 2013 PMID: 23527249 PMCID: PMC3602035 DOI: 10.1371/journal.pone.0059678
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Vasorelaxation kinetics parameters, percent vasorelaxation, and rate of vasorelaxation in the aorta, iliac, and femoral in control (C), diabetic (D), resistance training diabetic (RD), moderate (MD)- and high (HD)-intensity endurance training diabetic groups.
| Aorta | Iliac | Femoral | |||||||||||||
| C (n = 10) | D (n = 10) | RD (n = 10) | MD(n = 9) | HD (n = 10) | C (n = 10) | D (n = 9) | RD (n = 10) | MD(n = 8) | HD (n = 10) | C (n = 10) | D (n = 9) | RD (n = 10) | MD (n = 7) | HD (n = 10) | |
| τ Vasorelaxation (s) | 8.4 | 11.0 | 8.7 | 10.3 | 6.9 (1.2) | 6.1 | 8.2 | 8.2 | 7.7 | 4.7 (0.9) | 7.0 | 7.8 | 7.9 | 7.7 | 4.4 (0.5) |
| CTD Vasorelaxation (s) | 7.1 (2.1) | 3.8 (0.9) | 4.3 (0.7) | 5.7 (0.9) | 4.4 (0.7) | 4.7 (1.3) | 4.2 (3.2) | 6.1 (3.0) | 5.4 (1.5) | 3.4 (1.0) | 5.6 (2.2) | 4.3 (4.0) | 5.6 (2.4) | 4.7 (0.8) | 4.0 (1.1) |
| Time-to-steady-state (s) | 40.7 | 47.7 | 39.1 | 46.7 | 32.1 (4.8) | 29.0 | 37.0 | 39.0 | 36.2 | 22.1 (4.1) | 33.7 | 35.7 | 37.3 | 35.5 | 21.8 (2.2) |
| Vasorelaxation (%) | 33.0 (7.2) | 59.9(18.1) | 55.1 (12.5) | 64.1(23.7) | 44.8 (10.6) | 62.5 (21.2) | 50.2 (16.7) | 62.2 (6.9) | 48.5 (16.2) | 56.4 (11.0) | 80.0 (13.3) | 81.0 (17.7) | 75.1 (18.7) | 91.0 (9.7) | 84.2 (9.4) |
| Rate of vasorelaxation (%·s−1) | 0.9 | 1.3 | 1.5 | 1.5 | 1.4 (0.4) | 2.3 | 1.5 | 1.9 | 1.7 | 2.7 (0.8) | 2.7 | 3.3 | 2.4 | 3.0 | 3.9 (0.5) |
| Vasorelaxation ACh+L-NAME (%) | −1 (3) | 1 (3) | −2 (2) | −2 (3) | −1 (2) | −3 (4) | −1 (5) | −3 (6) | −3 (6) | −3 (6) | 5 (14) | 5 (10) | 2 (9) | 1 (7) | 3 (7) |
| Vasorelaxation SNP (%) | 92 (7) | 98 (2) | 96 (2) | 95 (5) | 95 (3) | 93 (4) | 97 (3) | 95 (4) | 94 (3) | 92 (3) | 99 (4) | 101 (6) | 99 (4) | 99 (1) | 97 (7) |
Values are means ± (SD). C, control animals; D, diabetic animals; RD, resistance trained diabetic animals; MD, moderate intensity endurance trained diabetic animals; HD, high intensity endurance trained animals; n, number of animals; τ, time constant for the vasorelaxation response; CTD, calculated time delay for the vasorelaxation response; Time-to-steady-state, CTD +4 τ; Rate of vasorelaxation, percent vasorelaxation/time-to-steady-state; L-NAME, NG-nitro-L-arginine methyl ester; SNP, sodium nitroprusside;
significantly different from HD (p<0.05);
significantly different from D (p<0.05);
femoral significantly different from aorta (p<0.05);
femoral significantly different from iliac (p<0.05).
iliac significantly different from aorta (p<0.05).
Figure 1Time constant (τ) (A), calculated time delay (CTD) (B), and time-to-steady-state (C), responses for each vessel and group.
Values are means ± (SD). D, diabetic animals; RD, resistance trained diabetic animals; MD, moderate intensity endurance trained diabetic animals; HD, high intensity endurance trained animals; *significantly different from HD (p<0.05); †significantly different from D (p<0.05).
Figure 2Rate of vasorelaxation for each and group.
Values are means ± (SD). D, diabetic animals; RD, resistance trained diabetic animals; MD, moderate intensity endurance trained diabetic animals; HD, high intensity endurance trained animals; *significantly different from HD (p<0.05).
Figure 3e-NOS protein content and e-NOS content normalized to the lumen-to-wall-ratio for each vessel and group.
Values are means ± (SD). D, diabetic animals; RD, resistance trained diabetic animals; MD, moderate intensity endurance trained diabetic animals; HD, high intensity endurance trained animals; n, number of animals; *significantly different from HD (p<0.05).